Stanik-Hutt Julie A
Johns Hopkins University School of Nursing, and Inpatient Cardiology Nurse Practitioner Service, Department of Nursing, Johns Hopkins Hospital, Baltimore, MD 21205, USA.
J Cardiovasc Nurs. 2004 Nov-Dec;19(6):404-8. doi: 10.1097/00005082-200411000-00012.
Since its introduction in 1977, the success of percutaneous interventional cardiology has been limited by the occurrence of restenosis. Drug-eluting stents, particularly sirolimus- and paclitaxel-coated stents, have been shown in randomized controlled trials to dramatically reduce restenosis in single, de novo, native coronary arteries. Over the last 2 years, investigators have reported that these stents can also reduce restenosis in more complex patient situations such as in diabetics, during acute coronary syndromes, in long atherosclerotic lesions and small arteries, and even after in-stent restenosis. These outcomes increase the clinical value of this technology to "real world" practice. This article reviews the current state of our knowledge regarding drug-eluting stents and identifies areas for further research.
自1977年经皮介入心脏病学问世以来，再狭窄的发生一直限制着其成功应用。随机对照试验表明，药物洗脱支架，尤其是西罗莫司涂层支架和紫杉醇涂层支架，能显著降低单支、初发、天然冠状动脉的再狭窄率。在过去两年中，研究人员报告称，这些支架在更复杂的患者情况中也能降低再狭窄率，如糖尿病患者、急性冠状动脉综合征患者、长动脉粥样硬化病变和小动脉患者，甚至是支架内再狭窄患者。这些结果提高了这项技术在“现实世界”实践中的临床价值。本文回顾了我们目前关于药物洗脱支架的知识状况，并确定了需要进一步研究的领域。
